Biologics

Therapeutic antibodies
#Absci #AI #AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Biologics #Generative AI #Machine learning

How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Machine learning: developing next generation antibody therapeutics’. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and… Read More

#Featured Podcasts #Podcasts

Antibodies
#Biologics #Drug discovery #eBook #Thermal stability testing

Free resource: Your guide to faster, smarter biologics testing

Thermal stability testing is essential in biotherapeutic development—ensuring safety, efficacy, and shelf-life. It also helps predict aggregation and guides formulation and storage decisions. A new eBook ‘Thermal Stability Technology Selection Guide for Biotherapeutic Drug Development’ is now available to download for free from Waters / TA Instruments. Read this… Read More

#News

#Biologics #Drug discovery #eBook #Thermal stability testing

Your Guide to Faster, Smarter Biologics Testing

Thermal stability testing is essential in biotherapeutic development—ensuring safety, efficacy, and shelf-life. It also helps predict aggregation and guides formulation and storage decisions. Read this eBook to learn: Core techniques used in today’s labs Pros and cons of each method How to choose the right solution for your workflow Real-world… Read More

#eBooks #Resources

#Artificial intelligence (AI) #Biologics #Drug discovery

Enabling AI in chemistry and biologics discovery

This paid-for advertorial from CDD Vault appeared in DDW Volume 26 – Issue 4, Fall 2025   CDD Vault outlines what to look for in an SDMP across chemistry and biologics using examples from CDD Vault and other leading platforms.  AI and machine learning are accelerating structure-activity relationship (SAR) predictions… Read More

#Exclusive Content

Female researcher in a laboratory
#Biologics #Biomanufacturing #Monoclonal antibodies #Phylloceuticals #Plant-based

US company hopes to transform access to advanced biologics

Phylloceuticals has announced the successful production of its first batch of a PD-1 inhibitor monoclonal antibody (mAb) just 12 weeks after initiating operations in its new laboratory space in Rapid City, South Dakota, US.   The company says the achievement marks a potential paradigm shift in how complex… Read More

#News

Antibodies
#Absci #Antibodies #Biologics #Biopharmaceuticals #Clinical trials

Absci becomes clinical-stage company with clinical trial initiation

Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More

#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Drivers and challenges in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Therapeutic antibody innovation

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar highlights innovation in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry. You will hear from Aron Knickerbocker, CEO of Aulos Bioscience, and Martin… Read More

Webinar date:
Sponsored by Bio-Rad
#Webinars

#Biologics #Cell line development #Cell lines #Drug discovery #Proteins

Where do we stand with cell line development?

DDW’s Megan Thomas examines the value and impact of cell line development in the drug discovery industry. When it comes to the creation of biologics, cell line development is an essential drug discovery process. From a functional perspective, when it comes to monoclonal antibodies (mAbs), enzymes, or other therapeutic proteins,… Read More

#Exclusive Content

European Union and African Union flags
#Biologics #Collaboration #Immunology / Virology & Vaccines #mRNA-based vaccines #RNA

African European alliance to advance RNA-based vaccines

A new African European collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines.  A Memorandum of Understanding was signed by Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences during the… Read More

#News

Vaccine research
#Biologics #Chiesi #Manufacturing #Monoclonal antibodies

Chiesi opens €400m Biotech Center of Excellence in Italy

Chiesi Group has launched its Biotech Center of Excellence, dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins, in Parma, Italy. From the production of drug substances from mammalian cells to their transformation into drug products and final packaging, the company says that everything will be done in… Read More

#Business & Investment #News

CT scans of the brain
#Alzheimer's #Antibodies #Biogen #Biologics #Eisai #Neurodegenerative disorders

Data demonstrate long-term effect of lecanemab in early Alzheimer’s

Lecanemab-irmb (Leqembi), an anti-amyloid beta (Aβ) protofibril antibody, continues to show benefit for early Alzheimer’s disease (AD) patients over three years, according to new trial results. Eisai and Biogen shared the latest findings at the Alzheimer’s Association International Conference (AAIC) 2024, held in Philadelphia. Read More

#News

Biologic drugs
#Asthma #Biologics #Eczema #Glen Clova Scientific #Start-ups #University of Dundee

Improving the standard of biological drugs

DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More

#Exclusive Content #Start-up Zone